Full Text View
Tabular View
No Study Results Posted
Related Studies
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
This study has been completed.
First Received: February 10, 2004   Last Updated: May 13, 2009   History of Changes
Sponsored by: Hoffmann-La Roche
Information provided by: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00077636
  Purpose

This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.


Condition Intervention Phase
Hepatitis C, Chronic
Drug: peginterferon alfa-2a (40KD) [PEGASYS]
Drug: Copegus
Phase IV

MedlinePlus related topics: Hepatitis Hepatitis C
Drug Information available for: Ribavirin Peginterferon Alfa-2a Interferons
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Open-Label Study of the Effect of PEGASYS and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • SVR [ Time Frame: 24 weeks post-treatment (ie week 40 or week 48) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Virological response [ Time Frame: End of treatment (ie week 16 or week 24) ] [ Designated as safety issue: No ]
  • Virological response [ Time Frame: 12 weeks post-treatment (ie week 28 or week 36) ] [ Designated as safety issue: No ]
  • AEs, laboratory parameters, vital signs. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 1469
Study Completion Date: March 2006
Arms Assigned Interventions
1: Experimental Drug: peginterferon alfa-2a (40KD) [PEGASYS]
180 micrograms sc weekly for 16 weeks
Drug: Copegus
400mg po bid for 16 weeks
2: Experimental Drug: peginterferon alfa-2a (40KD) [PEGASYS]
180 micrograms sc weekly for 24 weeks
Drug: Copegus
400mg po bid for 24 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients >=18 years of age;
  • CHC infection (genotype 2 or 3);
  • liver biopsy (in <24 calendar months of first dose), with results consistent with CHC infection;
  • use of 2 forms of contraception during study and 6 months after the study in both men and women.

Exclusion Criteria:

  • women who are pregnant or breastfeeding;
  • male partners of women who are pregnant;
  • conditions associated with decompensated liver disease;
  • other forms of liver disease, including liver cancer;
  • human immunodeficiency virus infection;
  • previous treatment with an IFN, pegylated IFN, ribavirin, viramidine, levovirin, or amantadine.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00077636

  Hide Study Locations
Locations
United States, Alabama
BIRMINGHAM, Alabama, United States, 35294
MOBILE, Alabama, United States, 36693
United States, Alaska
ANCHORAGE, Alaska, United States, 99508
United States, Arizona
SCOTTSDALE, Arizona, United States, 85259
PHOENIX, Arizona, United States, 85006
United States, Arkansas
LITTLE ROCK, Arkansas, United States, 72205
United States, California
LONG BEACH, California, United States, 90822
LA JOLLA, California, United States, 92037-1030
PALO ALTO, California, United States, 94304-1509
SAN DIEGO, California, United States, 92154
SAN FRANCISCO, California, United States, 94121
SAN FRANCISCO, California, United States, 94115
LOS ANGELES, California, United States, 90048
SACRAMENTO, California, United States, 95825-2115
SAN DIEGO, California, United States, 92105
SAN DIEGO, California, United States, 92123
SAN LUIS OBISPO, California, United States, 93401
United States, Colorado
LITTLETON, Colorado, United States, 80120
United States, Connecticut
FARMINGTON, Connecticut, United States, 06030
United States, Florida
SARASOTA, Florida, United States, 34243
MIAMI, Florida, United States, 33136
WELLINGTON, Florida, United States, 33414
GAINESVILLE, Florida, United States, 32610-0214
JACKSONVILLE, Florida, United States, 32209
JACKSONVILLE, Florida, United States, 32207
ORLANDO, Florida, United States, 32803
TAMPA, Florida, United States, 33612
PENSACOLA, Florida, United States, 32514
United States, Georgia
AUSTELL, Georgia, United States, 30106
ATLANTA, Georgia, United States, 30309
United States, Hawaii
HONOLULU, Hawaii, United States, 96817
United States, Idaho
BOISE, Idaho, United States, 83702
United States, Illinois
MOLINE, Illinois, United States, 61265
United States, Indiana
INDIANAPOLIS, Indiana, United States, 46202
United States, Iowa
IOWA CITY, Iowa, United States, 52242
IOWA CITY, Iowa, United States, 52246
United States, Louisiana
NEW ORLEANS, Louisiana, United States, 70112
BATON ROUGE, Louisiana, United States, 70805
United States, Maryland
BALTIMORE, Maryland, United States, 21205
BALTIMORE, Maryland, United States, 21201
United States, Massachusetts
BOSTON, Massachusetts, United States, 02118
BURLINGTON, Massachusetts, United States, 01805
BOSTON, Massachusetts, United States, 02720
WORCESTER, Massachusetts, United States, 01655
United States, Michigan
DETROIT, Michigan, United States, 48202-2689
ANN ARBOR, Michigan, United States, 48109-0362
United States, Minnesota
PLYMOUTH, Minnesota, United States, 55446
MINNEAPOLIS, Minnesota, United States, 55417
United States, Missouri
ST LOUIS, Missouri, United States, 63104
United States, New Mexico
ALBUQUERQUE, New Mexico, United States, 87108
United States, New York
BRONX, New York, United States, 10468
MANHASSET, New York, United States, 11030
WILLIAMSVILLE, New York, United States, 14221
NEW YORK, New York, United States, 10003
NEW YORK, New York, United States, 10021
BINGHAMTON, New York, United States, 13903
BAYSIDE, New York, United States, 11358
United States, North Carolina
CHAPEL HILL, North Carolina, United States, 27599-7080
CHARLOTTE, North Carolina, United States, 28203
DURHAM, North Carolina, United States, 27710
FAYETTEVILLE, North Carolina, United States, 28304
United States, Ohio
CINCINNATI, Ohio, United States, 45267-0595
CLEVELAND, Ohio, United States, 44106
United States, Oregon
PORTLAND, Oregon, United States, 97220
United States, Pennsylvania
PITTSBURGH, Pennsylvania, United States, 15213
LANCASTER, Pennsylvania, United States, 17604-3200
HERSHEY, Pennsylvania, United States, 17033
United States, Rhode Island
PROVIDENCE, Rhode Island, United States, 02905
CRANSTON, Rhode Island, United States, 02920
United States, Tennessee
GERMANTOWN, Tennessee, United States, 38138
United States, Texas
DALLAS, Texas, United States, 75235-9151
FORT SAM HOUSTON, Texas, United States, 78234-3879
HOUSTON, Texas, United States, 77030
Dallas, Texas, United States, 75203
United States, Utah
SALT LAKE CITY, Utah, United States, 84121
United States, Vermont
WHITE RIVER JUNCTION, Vermont, United States, 05009-0001
United States, Virginia
RICHMOND, Virginia, United States, 23249
CHESAPEAKE, Virginia, United States, 23320-1706
CHARLOTTESVILLE, Virginia, United States, 22902
FALLS CHURCH, Virginia, United States, 22042
United States, Washington
SEATTLE, Washington, United States, 98195
KIRKLAND, Washington, United States, 98034
SEATTLE, Washington, United States, 98133
BELLEVUE, Washington, United States, 98004
SPOKANE, Washington, United States, 99220-3649
PUYALLUP, Washington, United States, 98372
United States, Wisconsin
MADISON, Wisconsin, United States, 53792
United States, Wyoming
CHEYENNE, Wyoming, United States, 82001
Australia
WOOLLOONGABBA, Australia, 4102
BRISBANE, Australia, 4029
MELBOURNE, Australia, 3181
ADELAIDE, Australia, 5000
KINGSWOOD, Australia
Canada, Alberta
EDMONTON, Alberta, Canada, T6G 2B7
Canada, Ontario
DOWNSVIEW, Ontario, Canada, M3N 2V7
MISSISSAUGA, Ontario, Canada, L5M 2V8
France
VANDOEUVRE-LES-NANCY, France, 54511
TOULOUSE, France, 31059
CRETEIL, France, 94010
NICE, France, 06202
GRENOBLE, France, 38043
RENNES, France, 35033
CLICHY, France, 92118
STRASBOURG, France, 67091
MARSEILLE, France, 13001
Germany
HOMBURG, Germany, 66424
KIEL, Germany, 24105
BERLIN, Germany, 13353
FREIBURG, Germany, 79106
DÜSSELDORF, Germany, 40225
HANNOVER, Germany, 30623
Italy
PISA, Italy, 56124
MILANO, Italy, 20121
BOLOGNA, Italy, 40138
BERGAMO, Italy, 24128
NAPOLI, Italy, 80131
PAVIA, Italy, 27100
New Zealand
OTAHUHU, New Zealand
Puerto Rico
SANTURCE, Puerto Rico, 00909
PONCE, Puerto Rico, 00716
SAN JUAN, Puerto Rico, 00936-5067
SAN JUAN, Puerto Rico, 00921-3200
Spain
VALENCIA, Spain, 46014
SEVILLA, Spain, 41013
MADRID, Spain, 28006
BARCELONA, Spain, 08803
MADRID, Spain, 28007
BARAKALDO, Spain, 48903
MADRID, Spain, 28034
BARCELONA, Spain, 08025
MADRID, Spain, 08029
BADALONA, Spain, 08915
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche, +1 973 235 5000
  More Information

No publications provided by Hoffmann-La Roche

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Responsible Party: Hoffmann-La Roche ( Clinical Trials, Study Director )
Study ID Numbers: NV17317
Study First Received: February 10, 2004
Last Updated: May 13, 2009
ClinicalTrials.gov Identifier: NCT00077636     History of Changes
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Antimetabolites
Interferon-alpha
Liver Diseases
Hepatitis, Chronic
Ribavirin
Interferons
Hepatitis, Viral, Human
Angiogenesis Inhibitors
Antiviral Agents
Hepatitis
Virus Diseases
Digestive System Diseases
Peginterferon alfa-2a
Hepatitis C
Interferon Alfa-2a
Hepatitis C, Chronic

Additional relevant MeSH terms:
Antimetabolites
Anti-Infective Agents
Liver Diseases
Flaviviridae Infections
Hepatitis, Chronic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Ribavirin
Physiological Effects of Drugs
Hepatitis, Viral, Human
Therapeutic Uses
Hepatitis C
Angiogenesis Modulating Agents
Growth Inhibitors
RNA Virus Infections
Growth Substances
Antiviral Agents
Angiogenesis Inhibitors
Pharmacologic Actions
Virus Diseases
Hepatitis
Digestive System Diseases
Peginterferon alfa-2a
Interferon Alfa-2a
Hepatitis C, Chronic

ClinicalTrials.gov processed this record on May 14, 2009